James “Jim” Sigg FDA's Deputy Commissioner for Operations and Chief Operating Officer | Official Website
James “Jim” Sigg FDA's Deputy Commissioner for Operations and Chief Operating Officer | Official Website
This is a 50% decrease from the number of companies inspected in the previous year, when four companies received four inspections.
The companies inspected were involved in the Biologics sector.
There was one company in line with FDA regulations who don’t need to adjust their management operations or regulatory/administrative actions. One should take voluntary action to correct the organization's management operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.
Company Name | Area of Business | Inspection Date | Result |
---|---|---|---|
Octapharma Plasma, Inc. | Biologics | 12/20/2024 | Voluntary Action Indicated (VAI) |
Versiti Indiana, Inc. | Biologics | 02/23/2024 | No Action Indicated (NAI) |